🇺🇸 FDA
Patent

US 10864206

Treatment of neurodegenerative conditions by disruption of Rhes

granted A61KA61K31/12A61K31/223

Quick answer

US patent 10864206 (Treatment of neurodegenerative conditions by disruption of Rhes) held by The Regents of the University of California expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Dec 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/12, A61K31/223, A61K31/4545, A61K31/4709